by MarketingWP-Admin | Jan 24, 2020 | Benefits of Qimono, Qimono, Supporting papers for CSTD
Tests to evaluate the effectiveness of closed system transfer devices in preventing exposure to dangerous chemotherapy drugs, has proven Vygon’s Qimono exceeds the rigorous NIOSH (National Institute for Occupational Safety and Health) standards. The results show...
by MarketingWP-Admin | Aug 5, 2019 | Events, Qimono
In a little over four months, Telford will be the venue for this year’s UKONS conference. The theme is Cancer care; staying safe and there will be presentations on emotional safety, professional safety and patient and carer safety. We will be at UKONS to share the...
by MarketingWP-Admin | Aug 5, 2019 | Best Practice, Qimono
Cancer nurses across Europe are being encouraged to adopt the new EONS Safety Manifesto to protect them and their patients from the potential health risks of cytotoxic drugs. With exposure to chemotherapy used in cancer therapies linked to a number of problems ranging...
by Chaar Yeates | Nov 12, 2018 | Benefits of Qimono, Qimono
Tests to evaluate the compatibility of Qimono, Vygon’s closed system transfer device, with key cancer therapies have concluded the connectors would be compatible with all cytotoxic drug infusions in current clinical practice. The testing conducted by Professor Graham...
by Chaar Yeates | Nov 12, 2018 | Qimono
A new clinical study from the US shows a reduction in contamination risk of 97% when using a closed system transfer device (CSTD) to administer hazardous drugs. The US study* involved 13 cancer centres across the United States and the findings demonstrated that the...
by Chaar Yeates | Nov 12, 2018 | Qimono, SACTsafety
A yellow cover document from the NHS Specialist Pharmacy Service proposes a nine-point plan to minimise exposure to potentially dangerous systemic anti-cancer therapies. The ‘Guidance on Handling of Injectable Cytotoxic Drugs in Clinical Areas in NHS Hospitals in the...